Comparative evaluation of clinical outcomes of dapagliflozin and empagliflozin in type-2 diabetes mellitus.

Hakan Doğruel, Hatice Tülüce Atlım,Mustafa Aydemir,Nusret Yılmaz,Ramazan Sarı

Irish journal of medical science（2022）

引用 0|浏览2

暂无评分

摘要

Dapagliflozin and empagliflozin are the drugs to choose for renoprotection in diabetics independent of the use of a RAAS blocker. Even the time to addition of a new anti-diabetic agent is longer in the empagliflozin group, head-to-head comparative trials are needed to asess the potential differences in this regard.

查看译文

关键词

Dapagliflozin,Diabetes mellitus,Diabetic nephropathy,Empagliflozin,Renoprotection,Sodium-glucose transporter 2

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要